Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etripamil - Milestone Pharmaceuticals

Next Previous
X
Search
Drug Profile

Etripamil - Milestone Pharmaceuticals

Alternative Names: (-)-MSP-2017; CARDAMYST; MSP-2017; MSP-2017A; MSP-2017B

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Milestone Pharmaceuticals
  • Developer Corxel Pharmaceuticals; Milestone Pharmaceuticals
  • Class Amines; Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Paroxysmal supraventricular tachycardia
  • Phase II Atrial fibrillation
  • Phase I Unspecified
  • No development reported Angina pectoris

Most Recent Events

  • 10 Dec 2024 Milestone Pharmaceuticals plans a phase III ReVeRA-301 trial for Atrial fibrillation in June 2025 (Intranasal, Spray) (NCT06716021, MSP-2017-5002)
  • 12 Nov 2024 Milestone Pharmaceuticals plans to launch etripamil for patients with Paroxysmal supraventricular tachycardia in USA in 2025
  • 28 Oct 2024 Ji Xing Pharmaceuticals is now called Corxel Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top